Edwards Invests In Mitral, Tricuspid Solutions As TAVR Growth Exceeds Expectations
Sales of Sapien transcatheter aortic valves grew about 27% year over year in the third quarter of 2019 while revenues from Edwards’ transcatheter mitral and tricuspid therapies grew to almost $10m, led by sales of the Pascal transcatheter mitral repair system in Europe.
You may also be interested in...
Mussallem’s retirement at age 70 does not come as a surprise to the Street, but analysts expect some headwinds for his successor Bernard Zovighian, who has been heading the firm’s transcatheter mitral and tricuspid valve repair business.
Edwards Lifesciences received the CE mark for its PASCAL transcatheter system for treating triscupid valve regurgitation, competing against Abbott’s newly CE-marked TriClip.
Tendyne is indicated for the treatment of significant mitral regurgitation in patients who are not candidates for surgery. It complements Abbott’s MitraClip mitral valve repair device and is an important part of the company’s strategy to be the leading structural heart device company.